Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price Target
Assembly Biosciences, Inc.
Assembly Biosciences, Inc. ASMB | 0.00 |
Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:
ASMB) with a Buy and maintains $43 price target.
